Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents : Main results of the basel stent kosten-effektivitäts trial-prospective validation examination II (BASKET-PROVE II), A randomized, controlled noninferiority 2-year outcome trial

Circulation

Volumn 131, Issue 1, 2015, Pages 74-81

  Kaiser, Christoph ^a   Galatius, Soeren ^b   Jeger, Raban ^a   Gilgen, Nicole ^a   Jensen, Jan Skov ^b   Naber, Christoph ^c   Alber, Hannes ^d   Wanitschek, Maria ^d   Eberli, Franz ^e   Kurz, David J ^e   Pedrazzini, Giovanni ^f   Moccetti, Tiziano ^f   Rickli, Hans ^g   Weilenmann, Daniel ^g   Vuillomenet, André ^g   Steiner, Martin ^g   Von Felten, Stefanie ^a   Vogt, Deborah R ^a   Hansen, Kim Wadt ^b   Rickenbacher, Peter ^e   Conen, David ^a   Müller, Christian ^a   Buser, Peter ^a   Hoffmann, Andreas ^a   Pfisterer, Matthias ^a   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ELISABETH KRANKENHAUS ESSEN   (Germany)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^e Cardiocentro ^*  (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g State Hospital   (Switzerland)

Author keywords

Antiplatelet drugs; Clinical trial; Coronary arterydisease; Coronarythrombosis; Drug coated stents; Drug eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; EVEROLIMUS; POLYMER; PRASUGREL; SILICON CARBIDE; UMIROLIMUS; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; METAL; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; RAPAMYCIN; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATTRIBUTABLE RISK; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; STENT THROMBOSIS; SURVIVAL; VERY LATE STENT THROMBOSIS; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STENT; SWITZERLAND; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; ANTI-INFLAMMATORY AGENTS; ASPIRIN; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; METALS; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; POLYMERS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SINGLE-BLIND METHOD; SIROLIMUS; STENTS; SWITZERLAND; THIOPHENES; TREATMENT OUTCOME;

EID: 84925581904     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013520     Document Type: Article

References (27)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254-265.
2. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-181.
3. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
4. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Jüni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-399.
5. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.
6. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: A systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35:1147-1158.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW. Clinical outcomes with bioabsorbable polymer- versus durable polymerbased drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299-307.
8. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: Mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.
9. Natsuaki M, Kozuma K, Morimoto T, Shiomi H, Kimura T. Two year outcome of a randomized trial comparing second-generation drug-eluting stents using biodegradable or durable polymer. JAMA. 2014;311:2125-2127.
10. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, vanEs GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-1948.
11. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
12. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
13. Stefanini GG, Windecker S. Stent thrombosis: No longer an issue with newer-generation drug-eluting stents? Circ Cardiovasc Interv. 2012;5:332-335.
14. Kornowski R, Vaknin-Assa H, Ukabi S, Lev EI, Assali A. PROKinetic: results from an "all-comers" single centre clinical experience. EuroIntervention. 2009;5:109-114.
15. Jeger R, Pfisterer M, Alber H, Eberli F, Galatius S, Naber C, Pedrazzini G, Rickli H, Jensen JS, Vuilliomenet A, Gilgen N, Kaiser C. Newestgeneration drug-eluting and bare-metal stents combined with prasugrelbased antiplatelet therapy in large coronary arteries: The BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J. 2012;163:136-141.e1.
16. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Hear J. 2000;21:1502-1513.
17. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M; BASKET-PROVE Study Group. Drug-eluting versus baremetal stents in large coronary arteries. N Engl J Med. 2010;363:2310-2319.
18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344-2351.
19. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet. 2008;372:1163-1173.
20. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T; NEXT Investigators. Biodegradable polymer biolimuseluting stent versus durable polymer everolimus-eluting stent: A randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181-190.
21. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873-890.
22. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
23. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation. 1998;98:1875-1880.
24. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, Di Francesco L, Finci L, Di Mario C, Colombo A. Angiographic and clinical outcome following coronary stenting of small vessels: A comparison with coronary stenting of large vessels. J Am Coll Cardiol. 1998;32:1610-1618.
25. Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): A randomised, controlled, non-inferiority trial. Lancet. 2013;381:651-660.
26. Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularization (BIOSCIENCE): A randomized, single-blind, non-inferiority trial. Lancet. 2014, doi: 10.1016/S0140-6736(14)61038-2. [Epub ahead of print].
27. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308:2594-2604.